ArticleNPJ drug discovery2025
Revisiting the
Abstract read
In one paragraph
Article in NPJ drug discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- New thinking for the next generation of antimalarials.EMBO molecular medicine · 2026Review
- New thinking for the next generation of antimalarials.EMBO molecular medicine · 2026Review
- Integrating chemical, genetic, and feasibility assessments for anti-tubercular target validation.EMBO molecular medicine · 2026Review
- Protein Arginine Methyltransferase Inhibitors Target Multiple Stages ofACS infectious diseases · 2026Article
- A Novel Inhibitor against the Bromodomain Protein 1 of the Malaria Pathogen Plasmodium Falciparum.ChemMedChem · 2025Article
- Predicting Plasmodium drug resistance through in vitro evolution.Trends in parasitology · 2025Article
Corrections and comments
- Update of
Authors and funding
49 authors.
Karla P Godinez-Macias *Department of Pediatrics, University of California, San Diego, La Jolla, CA USA.
Daisy Chen *Department of Pediatrics, University of California, San Diego, La Jolla, CA USA.
J Lincoln WallisPanorama Global, 2101 4th Ave, Ste 2100, Seattle, WA USA.
Miles G SiegelLgenia, Inc., 412 S Maple St, Fortville, IN USA.
Anna AdamMMV Medicines for Malaria Venture, 1215, Geneva, Switzerland.
Selina BoppDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA USA.
Krypton CarolinoDepartment of Pediatrics, University of California, San Diego, La Jolla, CA USA.
Lauren B CoulsonHolistic Drug Discovery and Development (H3D) Centre, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Greg DurstLgenia, Inc., 412 S Maple St, Fortville, IN USA.
Vandana ThathyDepartment of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY USA.
Lisl EsherickDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA USA.
Madeline A FarringerDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA USA.
Erika L FlanneryGlobal Health, Biomedical Research, Novartis, Emeryville, CA USA.
Barbara ForteDrug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Science, University of Dundee, Dundee, UK.
Tiqing LiuSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA USA.
Luma Godoy MagalhaesDrug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Science, University of Dundee, Dundee, UK.
Anil K GuptaCalibr-Skaggs Institute for Innovative Medicines, a division of The Scripps Research Institute, La Jolla, CA USA.
Eva S IstvanDivision of Infectious Diseases, Washington University School of Medicine, Saint Louis, MO USA.
Tiantian JiangDepartment of Pediatrics, University of California, San Diego, La Jolla, CA USA.
Krittikorn KumpornsinCalibr-Skaggs Institute for Innovative Medicines, a division of The Scripps Research Institute, La Jolla, CA USA.
Karen LobbLgenia, Inc., 412 S Maple St, Fortville, IN USA.
Kyle J McLeanDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA USA.
Igor M R MouraDepartment of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY USA.
John OkomboDepartment of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY USA.
N Connor PayneDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA USA.
Andrew PlaterDrug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Science, University of Dundee, Dundee, UK.
Srinivasa P S RaoGlobal Health, Biomedical Research, Novartis, Emeryville, CA USA.
Jair L Siqueira-NetoDepartment of Pediatrics, University of California, San Diego, La Jolla, CA USA.
Bente A SomsenTropIQ Health Sciences, Nijmegen, The Netherlands.
Robert L SummersDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA USA.
Rumin ZhangGlobal Health Drug Discovery Institute, Beijing, China.
Michael K GilsonSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA USA.
Francisco-Javier GamoGlobal Health Medicines R&D, GlaxoSmithKline, Tres Cantos, Madrid, Spain.
Brice CampoMMV Medicines for Malaria Venture, 1215, Geneva, Switzerland.
Beatriz BaragañaDrug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Science, University of Dundee, Dundee, UK.
James DuffyMMV Medicines for Malaria Venture, 1215, Geneva, Switzerland.
Ian H GilbertDrug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Science, University of Dundee, Dundee, UK.
Amanda K LukensDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA USA.
Koen J DecheringTropIQ Health Sciences, Nijmegen, The Netherlands.
Jacquin C NilesDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA USA.
Case W McNamaraCalibr-Skaggs Institute for Innovative Medicines, a division of The Scripps Research Institute, La Jolla, CA USA.
Xiu ChengGlobal Health Drug Discovery Institute, Beijing, China.
Lyn-Marie BirkholtzDepartment of Biochemistry, Genetics & Microbiology, Institute for Sustainable Malaria Control, University of Pretoria, Private Bag X20, Hatfield, Pretoria, South Africa.
Alfred W BronkhorstTropIQ Health Sciences, Nijmegen, The Netherlands.
David A FidockDepartment of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY USA.
Dyann F WirthDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA USA.
Daniel E GoldbergDivision of Infectious Diseases, Washington University School of Medicine, Saint Louis, MO USA.
Marcus C S LeeDivision of Biological Chemistry and Drug Discovery, Wellcome Centre for Anti-Infectives Research, University of Dundee, Dundee, UK.
Elizabeth A WinzelerDepartment of Pediatrics, University of California, San Diego, La Jolla, CA USA.
Funding
The Graduate Program in Tropical Infectious Diseases (GPiTID)T32AI049928 · NIAID · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI Flaminia Catteruccia, Phyllis J. Kanki · 2001 to 2026
$5.0MDefining the resistome in P. falciparum: evolution and mechanismR01AI169892 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Daniel E. Goldberg, Elizabeth A Winzeler · 2023 to 2026
$4.4MDefining the Role of PfCRT and PfMDR1 as Pleiotropic Mediators of Plasmodium falciparum Multidrug ResistanceR37AI050234 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI David A Fidock · 2018 to 2026
$4.4MDefining P. falciparum resistance to artemisinin-based combination therapiesR01AI109023 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI FIDOCK, DAVID A · 2014 to 2025
$4.4MElucidating the molecular basis of piperaquine resistance in Plasmodium falciparumR01AI124678 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI David A Fidock · 2016 to 2026
$4.3MPlasmodium Protein Kinase Focused Antimalarials DiscoveryR01AI172066 · NIAID · UNIVERSITY OF CENTRAL FLORIDA · PI DEBOPAM CHAKRABARTI, NATHANAEL Schiander GRAY · 2022 to 2026
$3.9MGraduate Training Program in BioinformaticsT32GM139790 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BAFNA, VINEET, GAASTERLAND, THERESA · 2021 to 2025
$2.1MHotspotting Cardiometabolic Disparities for Simulated Advances in Population CareR01AG052533 · NIA · HEALTHPARTNERS INSTITUTE · PI WESTGARD, BJORN CHRISTOPHER · 2018 to 2021
$2.0MDefining the complex genetic basis of Plasmodium falciparum resistance to artemisinin and quinine and identifying resistance-refractory therapeuticsR01AI185559 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI David A Fidock · 2024 to 2026
$1.9MGates Foundation INV-033538NIAID NIH HHS R01 AI109023NIAID NIH HHS R01 AI124678NIAID NIH HHS R01 AI169892NIAID NIH HHS R01 AI172066NIAID NIH HHS R01 AI185559NIAID NIH HHS R37 AI050234NIAID NIH HHS T32 AI049928NIA NIH HHS R01 AG052533NIGMS NIH HHS T32 GM139790
Abstract
Identification of novel drug targets is a key component of modern drug discovery. While antimalarial targets are often identified through the mechanism of action studies on phenotypically derived inhibitors, this method tends to be time- and resource-consuming. The discoverable target space is also constrained by existing compound libraries and phenotypic assay conditions. Leveraging recent advances in protein structure prediction, we systematically assessed the
Indexed as
Target identificationTarget validation
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.